Peripheral blood markers predict prognosis in patients with advanced non-small cell lung cancer receiving immunotherapy
CRP and CEA hold the potential to predict the prognosis of advanced NSCLC patients undergoing first-line immunotherapy, with independent predictors for both progression-free survival and overall survival.